BriaCell Therapeutics - Warrants (24/02/2025) Total Current Liabilities

The latest total current liabilities for BCTXW is $3.6M as of April 2026. That compares with $4.3M in the prior-year period — down 17.1% year over year. Investors often review this figure alongside BriaCell Therapeutics - Warrants (24/02/2025)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, BCTXW's total current liabilities moved from $4.3M to $3.6M — a 17.1% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in BriaCell Therapeutics - Warrants (24/02/2025)'s operating scale or balance-sheet position.

A total current liabilities figure of $3.6M for BCTXW is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting BCTXW's total current liabilities ($3.6M), review year-over-year change from $4.3M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack BriaCell Therapeutics - Warrants (24/02/2025)'s total current liabilities against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.